JP2018510894A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510894A5 JP2018510894A5 JP2017552890A JP2017552890A JP2018510894A5 JP 2018510894 A5 JP2018510894 A5 JP 2018510894A5 JP 2017552890 A JP2017552890 A JP 2017552890A JP 2017552890 A JP2017552890 A JP 2017552890A JP 2018510894 A5 JP2018510894 A5 JP 2018510894A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- administration
- pharmaceutical composition
- days
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012423 maintenance Methods 0.000 claims description 35
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 claims description 34
- 229960000635 paliperidone palmitate Drugs 0.000 claims description 22
- 210000000852 deltoid muscle Anatomy 0.000 claims description 15
- 210000003205 muscle Anatomy 0.000 claims description 12
- 208000020925 Bipolar disease Diseases 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- -1 paliperidone palmitate ester Chemical class 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 33
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229960001057 paliperidone Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144054P | 2015-04-07 | 2015-04-07 | |
| US62/144,054 | 2015-04-07 | ||
| US201562162596P | 2015-05-15 | 2015-05-15 | |
| US62/162,596 | 2015-05-15 | ||
| PCT/US2016/024841 WO2016164218A1 (en) | 2015-04-07 | 2016-03-30 | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019231631A Division JP7228503B2 (ja) | 2015-04-07 | 2019-12-23 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510894A JP2018510894A (ja) | 2018-04-19 |
| JP2018510894A5 true JP2018510894A5 (enExample) | 2019-05-09 |
| JP6728221B2 JP6728221B2 (ja) | 2020-07-22 |
Family
ID=57072843
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552890A Active JP6728221B2 (ja) | 2015-04-07 | 2016-03-30 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
| JP2019231631A Active JP7228503B2 (ja) | 2015-04-07 | 2019-12-23 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
| JP2021086909A Active JP7422277B2 (ja) | 2015-04-07 | 2021-05-24 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019231631A Active JP7228503B2 (ja) | 2015-04-07 | 2019-12-23 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
| JP2021086909A Active JP7422277B2 (ja) | 2015-04-07 | 2021-05-24 | 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10143693B2 (enExample) |
| EP (3) | EP3744326B1 (enExample) |
| JP (3) | JP6728221B2 (enExample) |
| KR (3) | KR20250013293A (enExample) |
| AU (4) | AU2016244801B2 (enExample) |
| BR (1) | BR112017021383A2 (enExample) |
| CA (2) | CA3088401A1 (enExample) |
| CY (1) | CY1123203T1 (enExample) |
| DK (2) | DK3744326T3 (enExample) |
| EA (1) | EA037185B1 (enExample) |
| ES (2) | ES2802299T3 (enExample) |
| FI (1) | FI3744326T3 (enExample) |
| HR (2) | HRP20201027T1 (enExample) |
| HU (2) | HUE049485T2 (enExample) |
| IL (3) | IL309340B1 (enExample) |
| LT (2) | LT3280416T (enExample) |
| MA (1) | MA41917B1 (enExample) |
| MD (2) | MD3744326T2 (enExample) |
| NZ (1) | NZ735952A (enExample) |
| PL (2) | PL3280416T3 (enExample) |
| PT (2) | PT3744326T (enExample) |
| RS (2) | RS60510B1 (enExample) |
| SI (2) | SI3744326T1 (enExample) |
| SM (2) | SMT202000351T1 (enExample) |
| TW (1) | TWI694825B (enExample) |
| UA (1) | UA118732C2 (enExample) |
| WO (1) | WO2016164218A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000351T1 (it) | 2015-04-07 | 2020-09-10 | Janssen Pharmaceuticals Inc | Regime di dosaggio per dosi mancate per esteri di paliperidone iniettabili ad azione prolungata |
| US11666573B2 (en) | 2017-10-27 | 2023-06-06 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
| PL4025187T3 (pl) | 2020-11-30 | 2024-04-29 | Janssen Pharmaceutica Nv | Schematy dawkowania związane z formulacjami paliperydonu do wstrzykiwania o przedłużonym uwalnianiu |
| EP4025189B1 (en) | 2020-11-30 | 2024-06-05 | Janssen Pharmaceutica NV | Dosing regimens associated with extended release paliperidone injectable formulations |
| WO2022111859A1 (en) * | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| MX2023006369A (es) * | 2020-11-30 | 2023-08-09 | Janssen Pharmaceutica Nv | Metodos para asegurar resuspension de formulaciones de palmitato de paliperidona. |
| US12472184B2 (en) | 2021-08-20 | 2025-11-18 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| US20230085549A1 (en) * | 2021-08-30 | 2023-03-16 | Janssen Pharmaceutica Nv | Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations |
| KR102869809B1 (ko) | 2023-11-21 | 2025-10-13 | 주식회사 엘지에너지솔루션 | 양극 및 이를 포함하는 전고체 전지 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| US20080214808A1 (en) | 2005-04-25 | 2008-09-04 | Thomas Frederik Ernestine Spittaels | Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester |
| KR20100099292A (ko) * | 2007-12-19 | 2010-09-10 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| WO2011042453A1 (en) * | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| AU2010313290A1 (en) | 2009-10-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Dosing regimen associated with long-acting injectable paliperidone esters |
| PT2529757E (pt) * | 2011-05-31 | 2014-02-27 | Rovi Lab Farmaceut Sa | Formulação para implante de paliperidona |
| SMT202000351T1 (it) | 2015-04-07 | 2020-09-10 | Janssen Pharmaceuticals Inc | Regime di dosaggio per dosi mancate per esteri di paliperidone iniettabili ad azione prolungata |
-
2016
- 2016-03-30 SM SM20200351T patent/SMT202000351T1/it unknown
- 2016-03-30 EP EP20169861.0A patent/EP3744326B1/en active Active
- 2016-03-30 ES ES16777058T patent/ES2802299T3/es active Active
- 2016-03-30 HU HUE16777058A patent/HUE049485T2/hu unknown
- 2016-03-30 DK DK20169861.0T patent/DK3744326T3/da active
- 2016-03-30 HR HRP20201027TT patent/HRP20201027T1/hr unknown
- 2016-03-30 ES ES20169861T patent/ES2967585T3/es active Active
- 2016-03-30 KR KR1020257000920A patent/KR20250013293A/ko active Pending
- 2016-03-30 MD MDE20210632T patent/MD3744326T2/ro unknown
- 2016-03-30 HU HUE20169861A patent/HUE065435T2/hu unknown
- 2016-03-30 JP JP2017552890A patent/JP6728221B2/ja active Active
- 2016-03-30 EA EA201792209A patent/EA037185B1/ru unknown
- 2016-03-30 PL PL16777058T patent/PL3280416T3/pl unknown
- 2016-03-30 RS RS20200726A patent/RS60510B1/sr unknown
- 2016-03-30 DK DK16777058.5T patent/DK3280416T3/da active
- 2016-03-30 IL IL309340A patent/IL309340B1/en unknown
- 2016-03-30 PT PT201698610T patent/PT3744326T/pt unknown
- 2016-03-30 MD MDE20180155T patent/MD3280416T2/ro unknown
- 2016-03-30 LT LTEP16777058.5T patent/LT3280416T/lt unknown
- 2016-03-30 PL PL20169861.0T patent/PL3744326T3/pl unknown
- 2016-03-30 IL IL254669A patent/IL254669B2/en unknown
- 2016-03-30 MA MA41917A patent/MA41917B1/fr unknown
- 2016-03-30 LT LTEP20169861.0T patent/LT3744326T/lt unknown
- 2016-03-30 SM SM20230478T patent/SMT202300478T1/it unknown
- 2016-03-30 SI SI201631783T patent/SI3744326T1/sl unknown
- 2016-03-30 UA UAA201710765A patent/UA118732C2/uk unknown
- 2016-03-30 SI SI201630743T patent/SI3280416T1/sl unknown
- 2016-03-30 EP EP23214037.6A patent/EP4349323A3/en active Pending
- 2016-03-30 KR KR1020177031672A patent/KR102606678B1/ko active Active
- 2016-03-30 EP EP16777058.5A patent/EP3280416B1/en active Active
- 2016-03-30 HR HRP20240022TT patent/HRP20240022T1/hr unknown
- 2016-03-30 AU AU2016244801A patent/AU2016244801B2/en active Active
- 2016-03-30 NZ NZ735952A patent/NZ735952A/en unknown
- 2016-03-30 RS RS20231239A patent/RS65024B1/sr unknown
- 2016-03-30 FI FIEP20169861.0T patent/FI3744326T3/fi active
- 2016-03-30 PT PT167770585T patent/PT3280416T/pt unknown
- 2016-03-30 BR BR112017021383-4A patent/BR112017021383A2/pt not_active Application Discontinuation
- 2016-03-30 WO PCT/US2016/024841 patent/WO2016164218A1/en not_active Ceased
- 2016-03-30 KR KR1020237040260A patent/KR102755145B1/ko active Active
- 2016-04-01 TW TW105110443A patent/TWI694825B/zh active
- 2016-04-01 CA CA3088401A patent/CA3088401A1/en not_active Abandoned
- 2016-04-01 CA CA2925908A patent/CA2925908C/en active Active
- 2016-04-05 US US15/090,889 patent/US10143693B2/en active Active
-
2019
- 2019-12-23 JP JP2019231631A patent/JP7228503B2/ja active Active
-
2020
- 2020-07-06 CY CY20201100618T patent/CY1123203T1/el unknown
- 2020-09-21 AU AU2020239611A patent/AU2020239611B2/en active Active
-
2021
- 2021-05-24 JP JP2021086909A patent/JP7422277B2/ja active Active
-
2022
- 2022-08-23 AU AU2022221405A patent/AU2022221405B2/en active Active
-
2024
- 2024-10-31 AU AU2024227790A patent/AU2024227790A1/en active Pending
-
2025
- 2025-10-19 IL IL324059A patent/IL324059A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510894A5 (enExample) | ||
| JP2013509435A5 (enExample) | ||
| JP2015187125A5 (enExample) | ||
| JP2017513809A5 (enExample) | ||
| CY1107262T1 (el) | Θεραπεια της εξαρτησης στερησης | |
| RU2008138381A (ru) | Режимы дозирования адреналина | |
| NZ599558A (en) | Dosing regimen associated with long-acting injectable paliperidone esters | |
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2015520196A5 (enExample) | ||
| JP2016514132A5 (enExample) | ||
| HRP20161533T1 (hr) | Supstance koje sadrže buprenorfin | |
| JP2017533972A5 (enExample) | ||
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| JP2019511506A5 (enExample) | ||
| FI3733712T3 (fi) | Hoito-ohjelmia ja menetelmiä pesäkekovettumataudin hoitamiseksi ofatumumabia käyttämällä | |
| JP2016515137A5 (enExample) | ||
| RU2017145643A (ru) | Фармацевтические композиции для пролонгированного высвобождения себакоил-диналбуфинового эфира | |
| JP2009539916A5 (enExample) | ||
| RU2008151727A (ru) | Комбинация аналогов соматостатина с антагонистом рецептора дофамина или рецептора гормона роста | |
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2014508174A5 (enExample) | ||
| BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
| SI2686002T1 (en) | A method for reducing influenza-like symptoms associated with intramuscular delivery of interferon by the rapid titration-enhancing regimen | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas |